Deposition of amyloid and tau pathology can be quantified in vivo using positron emission
tomography (PET). Accurate longitudinal measurements of accumulation from these images …

In the past decades, many neuroimaging studies have aimed to improve the scientific
understanding of human neurodegenerative diseases using MRI and PET. This article is …

Recent studies on Alzheimer's disease (AD) suggest that tau proteins spread through the
brain following neuronal connections. Several mechanisms could be involved in this …

Both plasma tau phosphorylated at threonine-181 (pTau181) and tau PET show potential for
detecting Alzheimer's disease (AD) pathology and predicting clinical progression. In this …

Tau accumulation starts during the preclinical phase of Alzheimer's disease and is closely
associated with cognitive decline. For preventive purposes, it is important to identify factors …

Background and Objectives Recently, the US Food and Drug Administration approved the
tau-binding radiotracer [18F] flortaucipir and an accompanying visual read method to …

The amyloid cascade hypothesis has strongly impacted the Alzheimer's disease research
agenda and clinical trial designs over the past decades, but precisely how amyloid-β …

Alzheimer's disease is characterized by regional reductions in cerebral blood flow (CBF).
Although the gold standard for measuring CBF is [15O] H2O PET, proxies of relative CBF …

Purpose Tau pathology is associated with concurrent atrophy and decreased cerebral blood
flow (CBF) in Alzheimer's disease (AD), but less is known about their temporal relationships …

Semiquantitative PET measures such as SUV ratio (SUVr) have several advantages over
quantitative measures, such as practical applicability and relative computational simplicity …